Brian Bonnell, chief financial officer of ICU Medical Inc., sold 6,381 shares of the company’s common stock on September 1, 2026, at $175 per share for a total of $1.12 million. The transaction was executed under a Rule 10b5-1 trading plan adopted by Bonnell on June 1, 2026. Following the sale, he retains direct ownership of 56,062 shares.
ICU Medical’s stock was trading at $170.81 on the same day, up 34% over the past 12 months. The company’s shares have a fair value estimate of $180.72, according to InvestingPro. Six analysts recently raised their earnings forecasts, with price targets ranging from $178 to $210. Raymond James maintained a Strong Buy rating while lifting its target to $200 from $180, citing double-digit growth in the company’s Infusion Systems segment.
ICU Medical reported adjusted second-quarter earnings per share of $2.37, exceeding Wall Street expectations of $1.91, and revenue of $548 million against a forecast of $533.4 million. The company raised its full-year adjusted EPS guidance to a range of $8.60 to $9.00, up from $7.75 to $8.45 previously, and also increased its adjusted EBITDA outlook.
S&P Global Ratings upgraded ICU Medical’s credit rating to BB from BB-, citing strengthened credit metrics, solid operating performance, and a reduction in leverage to 2.28 times as of June 30, 2026. The company also used approximately $250 million to repay debt in the period.
